



INFLUX HEALTHTECH LIMITED

Our Company was originally incorporated on September 28, 2020 as a Private Limited Company as “Influx Healthtech Private Limited” vide Registration No. 346825 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Central Registration Centre. Pursuant to a special resolution passed by the Shareholders at their Extra ordinary General Meeting held on May 09, 2022, our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to 'Influx Healthtech Limited' and a Fresh Certificate of Incorporation consequent to Conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U24299MH2020PLC346825. For further details of change in name and change in Registered Office of our Company, please refer to section titled 'History and Corporate Structure' beginning on 220 of Red Herring Prospectus.

**Registered Office:** 109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 Maharashtra, India, **Contact Person:** Mr. Atul Kumar Ashok Kumar Shukla, Company Secretary and Compliance Officer; Tel: +91 7045997809 ; E-mail: [cs@influxhealthtech.com](mailto:cs@influxhealthtech.com); Website: [www.influxhealthtech.com](http://www.influxhealthtech.com); CIN No: U24299MH2020PLC346825.

(PLEASE READ THE INSTRUCTIONS OVERLEAF AND IN THE RED HERRING PROSPECTUS DATED JUNE 11, 2025 CAREFULLY BEFORE FILLING IN THIS FORM)

To,  
The Board of Directors  
**INFLUX HEALTHTECH LIMITED**  
109, Ghanshyam Enclave Premises  
Co-op Soc Plot No. 856, Laljipada,  
Kandivali West, Mumbai - 400067  
Maharashtra, India

| BIDDING TIME:   | BOOK RUNNING LEAD MANAGER (BRLM)           | ANCHOR INVESTOR APPLICATION FORM NO. |
|---|--|--------------------------------------|
| 10:00 A.M. TO 04:00 P.M.  | RAREVER FINANCIAL ADVISORS PRIVATE LIMITED |                                      |
| In terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company, may in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size between ₹ 2 lakhs up to ₹ 10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Offer Price and not less than 35% of the Net offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see 'Offer Procedure' beginning on page 319 of Red Herring Prospectus. |  |                                      |

INITIAL PUBLIC OFFER OF UP TO 61,00,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF INFLUX HEATHTECH LIMITED ("OUR COMPANY" OR "IHL" OR "THE ISSUER") AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [●] LAKHS ("PUBLIC OFFER") COMPRISING OF A FRESH OFFER OF UP TO 50,00,400 EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS (THE "FRESH OFFER") AND AN OFFER FOR SALE OF UPTO 11,00,400 EQUITY SHARES BY THE PROMOTER SELLING SHAREHOLDER, MR. MUNIR ABDUL GANEE CHANDNIWALA ("OFFER FOR SALE") AGGREGATING TO ₹ [●] LAKHS, (HEREINAFTER REFFERD AS "PROMOTER SELLING SHAREHOLDER") OUT OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE OFFER (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC OFFER LESS MARKET MAKER RESERVATION PORTION I.E. OFFER OF [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE PUBLIC OFFER AND NET OFFER WILL CONSTITUTE [●] % AND [●] % RESPECTIVELY OF THE POST- OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

Dear Sir(s)/ Madam(s),

On the basis of the RHP dated June 11, 2025 and the Abridged Prospectus, the terms for Anchor Investors as mentioned therein, we hereby apply for application and subsequent allotment to us of the Equity Shares in the above offer upto our Bid for maximum number of Equity Shares at or above the Offer Price to be discovered through the Book Building Process. Our application in the Anchor Investor Portion is subject to the terms and conditions as specified in this Anchor Investor Application Form and the Abridged Prospectus. We hereby confirm that we are QIBs as defined under the SEBI ICDR Regulations and eligible to invest in the Offer in accordance with applicable laws. We undertake that we will sign all such other documents and do all such acts, if any, necessary on our part to enable us to be registered as the holder(s) of the Equity Shares which may be Allotted / Allocated to us. We authorise you to place our name on the register of members of the Company as holders of the Equity Shares that may be Allotted and to register our address as given below. We authorise the Company to make the necessary changes in this Anchor Investor Application Form and the RHP for final filing of Prospectus with the RoC without intimation to us and use this Anchor Investor Application Form as the Application form for the purpose of the Offer. We confirm that we, and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares, (A) are located outside the United States within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) and are purchasing the Equity Shares in an "offshore transaction" as defined in Regulation S, (B) understand that the Equity Shares have not been and will not be registered under the U.S. Securities Act or under the securities laws of any state of the United States or any other jurisdiction within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and (C) are not an affiliate of the Company or a person acting on behalf of such affiliate.

|                      |                                  |  |                              |                              |                              |                                 |                              |                               |  |                                   |  |
|----------------------|----------------------------------|--|------------------------------|------------------------------|------------------------------|---------------------------------|------------------------------|-------------------------------|--|-----------------------------------|--|
| Status<br>(Please ✓) | <input type="checkbox"/> FI      | Financial Institutions & Banks                       | <input type="checkbox"/> MF  | Mutual Funds                 | <input type="checkbox"/> IC  | Insurance Companies             | <input type="checkbox"/> FPI | Foreign Portfolio Investor    | (Other than Individual, Corporate Bodies & Family Offices) |                                   |  |
|                      | <input type="checkbox"/> SIDC    | State Industrial Development Corporation             | <input type="checkbox"/> AIF | Alternative Investment Funds | <input type="checkbox"/> VCF | Venture Capital Fund            | <input type="checkbox"/> PF  | Provident Funds/Pension Funds | <input type="checkbox"/> FVCI                              | Foreign Venture Capital Investors |  |
|                      | <input type="checkbox"/> SI-NBFC | Systemically Important Non-Banking Financial Company | <input type="checkbox"/> NIF | National Investment Fund     | <input type="checkbox"/> FIL | Foreign Institutional Investors | <input type="checkbox"/> OTH | Others (Please specify)_____  |  |                                   |  |

|                     |  |          |           |
|---------------------|--|----------|-----------|
| Name of the Bidder: |  |          |           |
| Address:            |  |          |           |
| Email ID :          |  | City:    | Pin code: |
| Telephone No:       |  | Fax No.: | Mobile:   |

|                             |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|-----------------------------|---|---|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| Depository Name (Please ✓)  | National Securities Depository Limited <input type="checkbox"/> |   |  |  |  |  |  | Central Depository Services (India) Limited <input type="checkbox"/>                             |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Depository Participant Name |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| DP - ID                     | I   | N |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Beneficiary Account Number  |   |   |  |  |  |  |  | (For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

| Bid Option | No. of Equity Shares Bid |            | Price per Equity Share |              |
|------------|--------------------------|------------|------------------------|--------------|
|            | (In Figures)             | (In Words) | (₹ In Figures)         | (₹ In Words) |
| Option 1   |                          |            |                        |              |
| Option 2   |                          |            |                        |              |
| Option 3   |                          |            |                        |              |

Permanent Account Number: 

|  |  |  |  |  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|--|--|--|--|
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|--|--|--|--|

Any application without PAN will be liable for rejection.

Paid ₹ \_\_\_\_\_ (₹ \_\_\_\_\_ only) through  
NEFT/RTGS Credit to IFS Code: \_\_\_\_\_, Account No.\*: \_\_\_\_\_ with \_\_\_\_\_ Bank.

\*[Please see Instruction No. (n)]

REPRESENTATIONS, WARRANTIES AND AGREEMENTS BY ANCHOR INVESTORS

We represent, warrant, acknowledge and agree with the Company and the BRLM as follows:

- In case of Resident Investors: We are a QIB as defined under the SEBI ICDR Regulations and resident of India and are not applying for the said Equity Shares as nominees of any person resident outside India or foreign nationals or Non-Residents.
- In case of Non-Resident Investors: We are a QIB as defined under the SEBI ICDR Regulations and have remitted funds for Equity Shares Bid through normal banking channels or out of funds held in Non-Resident External (NRE) account/ Foreign Currency Non-Resident (FCNR) account in India / any other account as may be permitted by the RBI.

For all Investors:

- We represent, warrant, acknowledge and agree with the Company and the BRLM as follows: (A) we have received a copy of the RHP and have read it and our investment decision is based solely on the RHP; (B) we have read and agreed to the representations, warranties, acknowledgements and agreements contained in (i) the sections titled as "Offer Procedure", "Terms of the Offer" and "Other Regulatory and Statutory Disclosures" of the RHP. We are and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares (A) are located outside the United States within the meaning of Regulation S under the Securities Act and am/are purchasing the Equity Shares in an "offshore transaction" as defined in Regulation S under the Securities Act and pursuant to the applicable laws of the jurisdictions where those offers and sales are made, and have read and agreed to the representations, warranties and agreements contained in the sections titled as "Offer Procedure", "Terms of the Offer" and "Other Regulatory and Statutory Disclosures" of the RHP; (B) We are not an affiliate of the Company or a person acting on behalf of such affiliate. (C) we understand that the Equity Shares have not been and will not be registered under the Securities Act or under the securities laws of any state of the United States or any other jurisdiction, and (D) we understand that the Equity Shares may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. (E) if we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, we have sole investment discretion with respect to each such account and we have full power to make the foregoing representations, warranties, acknowledgements and agreements on behalf of each such account; and (F) if we are making an application to acquire any of the Equity Shares for one or more managed accounts, we are authorized in writing by each such managed account to subscribe to the Equity Shares for each such managed account and to make (and we hereby make) the representations, warranties, acknowledgements and agreements herein for and on behalf of each such account reading the reference to "we" to include such accounts.
- We confirm that the bid size/ maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ ruling/ judgment of any regulatory, judicial or any other authority, including SEBI, or under the provisions of any law, regulation or statute including compliance with applicable Indian and foreign laws.
- We confirm that we are not one of the BRLM or any associate of the BRLM (other than (i) Mutual Funds sponsored by entities which are associates of the BRLM, (ii) insurance companies promoted by entities which are associate of the BRLM, (iii) AIFs sponsored by the entities which are associate of the BRLM, or (iv) FPIs other than Individual, corporate bodies & family offices sponsored by the entities which are associates of the BRLM) or Promoters of the Company or part of the Promoter Group of the Company or any person related to the Promoters or Promoter Group.
- We agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to us subject to the terms of the RHP, the GID, the Anchor Investor Application form and other Applicable Laws.
- Having read the terms for Anchor Investor Portion, we understand that, Anchor Investor would be required to pay the Bid Amount at the time of submission of the Anchor Investor Application Form. In the event of the Offer Price being higher than the Anchor Investor Allocation Price, the Anchor Investors shall be required to pay such additional amount to the extent of shortfall between the Anchor Investor Allocation Price and the Offer Price by the Pay-in Date mentioned in the revised CAN. If the Offer Price is lower than the Anchor Investor Allocation Price, the amount in excess of the Offer Price paid by Anchor Investors shall not be refunded to us.
- We further confirm that we will not offer, sell, pledge or transfer the Equity Shares for a period of 30 days from the date of Allotment.
- We confirm and represent that we have the requisite approvals and are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares in the Offer. We acknowledge the restrictions applicable to investment in the Company and the terms of the Offer.
- In case the information is incorrect or insufficient, the Bid is liable to be rejected and the Company and the BRLM would not be liable for losses, if any.
- For Non-Resident Bidders: I/we hereby confirm and certify that I/we am/are a 'fit and proper person' in accordance with the requirements prescribed under the Securities and Exchange Board of India (Intermediaries) Regulations, 2008 and as set out in the section 'Offer Procedure - Bid cum Application Form'.
- Disclosures for mutual funds: (i) Separate application can be made in respect of each scheme of a Mutual Fund registered with SEBI and such applications shall not be treated as multiple Bids, provided that such bids clearly indicate the scheme for which the bid is submitted (ii) Applications made by Asset Management Companies or custodian of Mutual Funds shall clearly indicate the name of the concerned scheme for which application is made.

**For FPI Bidders:** In case of FPI Investors utilizing the multiple investment manager structure in accordance with the operational guidelines for FPIs and designated Depository Participants issued to facilitate implementation of SEBI FPI Regulations (such structure referred to as "MIM Structure") Bids received from FPIs bearing the same PAN shall be treated as multiple Bids and are liable to be rejected, except for Bids from FPIs that utilize the MIM Structure provided such Bids have been made with different beneficiary account numbers. Client IDs and DP IDs. Accordingly, it should be noted that multiple Bids received from FPIs, who do not utilize the MIM Structure, and bear the same PAN, are liable to be rejected. In order to ensure valid Bids, FPIs making multiple Bids using the same PAN, and with different beneficiary account numbers, Client IDs and DP IDs, are required to provide a confirmation in the Anchor Investor Application Form that the relevant FPIs making multiple Bids utilize the MIM Structure. In the absence of such confirmation from the relevant FPIs, such multiple Bids shall be rejected and BRLM are not liable for losses, if any.

Date : \_\_\_\_\_, 2025

SIGNATURE OF THE BIDDER / AUTHORISED SIGNATORY

Note: Capitalised terms used and not defined herein shall have the respective meanings assigned to them in the RHP and Abridged Prospectus, as applicable.

TEAR HERE



INFLUX HEALTHTECH LIMITED

**Registered Office:** 109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 Maharashtra, India. **Contact Person:** Mr. Atul Kumar Ashok Kumar Shukla, Company Secretary and Compliance Officer; Tel: +91 7045997809 ; E-mail: [cs@influxhealthtech.com](mailto:cs@influxhealthtech.com); Website:[www.influxhealthtech.com](http://www.influxhealthtech.com); CIN No: U24299MH2020PLC346825.

Received from \_\_\_\_\_ Address \_\_\_\_\_

| Bid Option | No. of Equity Shares Bid |            | Price per Equity Share |              |
|------------|--------------------------|------------|------------------------|--------------|
|            | (In Figures)             | (In Words) | (₹ In Figures)         | (₹ In Words) |
| Option 1   |                          |            |                        |              |
| Option 2   |                          |            |                        |              |
| Option 3   |                          |            |                        |              |

NEFT/RTGS/NACH/Direct Credit for ₹ \_\_\_\_\_ (₹ \_\_\_\_\_ only) subject to confirmation by Axis Bank Limited, Escrow Collection Bank.

\*(Please See Instruction (N))

ANCHOR INVESTOR APPLICATION FORM NO.

Date : \_\_\_\_\_, 2025

Stamp & Signature of the BRLM

INSTRUCTIONS FOR ANCHOR INVESTORS

Participation by Anchor Investor in the Anchor Investor Portion and the subsequent Allotment of Equity Shares will be subject to the RHP and the Abridged Prospectus, including the following key terms:

- a) Anchor Investors shall mean QIBs applying under the Anchor Investor Portion in accordance with the requirements specified in the SEBI ICDR Regulations and the RHP.
- b) The Bid must be for a minimum of such number of Equity Shares such that Bid Amount is atleast ₹ 200 Lakhs and in multiples of 1200 Equity Shares and a Bid cannot be submitted for more than 60% of the QIB Portion under the Anchor Investor Portion. In terms of the Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019, as amended, the Offer of Equity Shares to a single FPI including its investor group must be below 10% of total paid-up Equity Share capital of the Company on a fully diluted basis. The aggregate limit is the sectoral caps applicable to Indian company as prescribed in the FEMA Rules in relation to its paid-up equity capital on a fully diluted basis. For further details see “Offer Procedure” and “Restrictions on Foreign Ownership of Indian Securities” beginning on page 319 and 365 of the RHP respectively.
- c) Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the DPIIT and the Foreign Exchange Management (Non-debt Instruments) Amendment Rules, 2020 which came into effect from April 22, 2020, any investment, subscription, purchase or sale of equity instruments by entities of a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country, will require prior approval of the Government of India, as prescribed in the Consolidated FDI Policy dated October 15, 2020 and the FEMA Rules.
- d) In case of a Mutual Fund, separate Bids by various schemes of a Mutual Fund will be aggregated to determine the minimum application size of ₹ 200 Lakhs.
- e) The BRLM shall accept the Bids from Anchor Investors during the Anchor Investor Bidding Date i.e. one Working Day prior to the Bid/Offer Opening Date and the Bidding shall be completed on the same day, which is Wednesday, Tuesday, June 17, 2025. Completed Anchor Investor Application Forms should be submitted to:

**RAREVER FINANCIAL ADVISORS PRIVATE LIMITED**  
807, Iconic Shyamal, Shyamal Cross Road, 132 Ring Road, Satellite, Manekbag, Ahmedabad, Gujarat, 380015 India  
Tel No.: 079-4925 8260  
**Email:** ipo.influxhealth@rarever.in, **Website:** www.rarever.in  
**Investor Grievances Email id** - IG@rarever.in  
**Contact Person:** Mr. Richi Shah/ Mr. Prerak Thakkar  
**SEBI Registration:** INM000013217

- f) The Company in consultation with the BRLM, will finalise the Anchor Investor Allocation Price within the Price Band at which allocation is made to Anchor Investors, without the prior approval of, or intimation to, the Anchor Investors. The Company in consultation with the BRLM reserve the right to reject Bids received from the Anchor Investors without assigning any reason therefor, in accordance with applicable law.
- g) The number of Equity Shares allocated to Anchor Investors and Anchor Investor Allocation Price, shall be made available in the public domain by the BRLM before the Bid/Offer Opening Date by intimating the Stock Exchanges i.e. NSE Limited.
- h) Anchor Investors are not allowed to Bid through the ASBA process. Anchor Investors are required to pay the full Bid Amount at the time of submission of the Bid.
- i) Anchor Investors cannot withdraw their Bids or lower the size of their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage, after the Anchor Investor Bidding date.
- j) In case Anchor Investor Allocation Price is lower than the Offer Price, the balance amount shall be payable by the pay-in date mentioned in the revised CAN. In case the Offer Price is lower than the Anchor Investor Allocation Price, the amount in excess of the Offer Price paid by the Anchor Investor, shall not be refunded to them.
- k) 50% of the Equity shares allotted to Anchor Investors in the anchor investor portion shall be locked in for a period of 90 days from the date of allotment while the remaining 50% of the Equity shares allotted to anchor investors in the anchor investor portion shall be locked in for a period of 30 days from the date of allotment.
- l) The BRLM or any of its associates cannot apply in the Offer under the Anchor Investor Portion, except for Mutual Funds sponsored by entities which are associate of the BRLM or insurance companies promoted by entities which are associates of the BRLM or AIFs sponsored by the entities which are associate of the BRLM or a FPI (other than individuals, corporate bodies and family offices) sponsored by entities which are associate of the BRLM. Further, members of the Syndicate, Promoters or the Promoter Group and any person related to them shall not participate in the Offer, except in accordance with the applicable law.
- m) Bids by QIBs under the Anchor Investor Portion and the QIB Portion shall not be considered as multiple Bids.
- n) The payment instruments for payment into the Escrow Account should be drawn in favour of:

| Bank              | IFSC Code   | Account No.     | Category     | Name of Escrow Account                    |
|-------------------|-------------|-----------------|--------------|---|
| AXIS BANK LIMITED | UTIB0000297 | 925020027420177 | Resident     | INFLUX HEALTHTECH LIMITED - ANCHOR R A/C  |
|                   |             | 925020027420261 | Non-Resident | INFLUX HEALTHTECH LIMITED - ANCHOR NR A/C |

- o) Non-Resident Bidders are required to comply with the ‘fit and proper person’ criteria in accordance with the requirements prescribed under the Securities and Exchange Board of India (Intermediaries) Regulations, 2008 and as set out in the section ‘Bid cum Application Form’. By certifying as a ‘fit and proper person’, Non-Resident Bidders confirm and certify that the following criteria are taken into consideration: (i) integrity, reputation and character; (ii) no convictions and restraint orders; (iii) competence, including having financial solvency and network; and (iv) no categorisations as a Wilful Defaulter
- p) A physical book will be prepared by the Registrar to the Offer on the basis of the Anchor Investor Application Forms. Based on the physical book and at the discretion of the Company in consultation with the BRLM, selected Anchor Investors will be sent a CAN and if required, a revised CAN. All Anchor Investors will be sent a CAN post the Anchor Investor Bid / Offer period and in the event that the Offer Price is higher than the price at which allocation is made to Anchor Investors, the Anchor Investors will be sent a revised CAN within one day of the Pricing Date indicating the number of Equity Shares allocated to such Anchor Investor and the pay-in date for payment of the balance amount. Anchor Investors should note that they shall be required to pay any additional amounts, being the difference between the Offer Price and the price at which allocation is made to Anchor Investors, as indicated in the revised CAN within the pay-in date referred to in the revised CAN. The revised CAN will constitute a valid, binding and irrevocable contract (subject to issue of Allotment Advice) for the Anchor Investor to pay the difference between the Offer Price and the price at which allocation is made to Anchor Investors and accordingly the Allotment Advice will be issued to such Anchor Investors. In the event the Offer Price is equal to or lower than the price at which allocation is made to Anchor Investors, the Anchor Investors who have been Allotted Equity Shares will directly receive Allotment Advice. The Allotment Advice shall be deemed a valid, binding and irrevocable contract for the Allotment of Equity Shares to such Anchor Investors.

The final allocation is subject to the physical application being valid in all respects along with receipt of stipulated documents, the Offer Price being finalised and Allotment by the Board of Directors or committee constituted by the Board of Directors.

- q) QIB who has any of the following rights shall be deemed to be a “person related to the Promoter/ Promoter Group”: (a) rights under a shareholders’ agreement or voting agreement entered into with the Promoter/ Promoter Group; (b) veto rights; or (c) right to appoint any nominee director on the Board of the Company. Further, an Anchor Investor shall be deemed to be an associate of the BRLM, if: (a) either of them controls, directly or indirectly through its subsidiary or holding company, not less than 15% of the voting rights in the other; or (b) either of them, directly or indirectly, by itself or in combination with other persons, exercises control over the other; or (c) there is a common director, excluding a nominee director, amongst the Anchor Investor and the BRLM.
- r) Allocation of Equity Shares to Anchor Investors at the Anchor Investor Allocation Price will be at the discretion of the Company, in consultation with the BRLM, subject to compliance with the following requirements:
  - i. not more than 60% of the QIB Portion will be allocated to Anchor Investors;
  - ii. one-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being done to other Anchor Investors; and
  - iii. allocation to Anchor Investors shall be on a discretionary basis and subject to:
    - a maximum of two Anchor Investors, where allocation in the Anchor Investor Portion is up to ₹ 200 Lakhs
    - minimum of two and maximum of 15 Anchor Investors, where the allocation under the Anchor Investor Portion is more than ₹ 200 Lakhs but up to ₹ 2500 Lakhs, under the Anchor Investor Portion, subject to a minimum Allotment of ₹ 100 Lakhs per Anchor Investor; and
    - in case of allocation above ₹ 2500 Lakhs under the Anchor Investor Portion, a minimum of five such investors and a maximum of 15 Anchor Investors for allocation up to ₹ 2500 Lakhs, and an additional 10 Anchor Investors for every additional ₹ 2500 lakhs or part thereof will be permitted, subject to minimum allotment of ₹ 100 Lakhs per Anchor Investor.
- s) In the event of under-subscription or non-allotment in the Anchor Investor Portion, the balance Equity Shares will be added to the Net QIB portion.
- t) This Anchor Investor Application Form is being issued to you on basis that you agree to abide by (1) this Anchor Investor Application Form and (2) the RHP with the terms and conditions contained therein.

For further details, please see "Offer Procedure" beginning on page 319 of the RHP.

**Note : Capitalised terms used and not defined herein shall have the respective meanings ascribed to them in the RHP and the Abridged Prospectus.**

----- TEAR HERE -----

All future communication in connection with Bids made in this Offer should be addressed to the Registrar to the Offer quoting the full name and address of the Applicant, PAN, Anchor Investor Application Form number, Bidders Depository Account Details, number of Equity Shares applied for, date of Anchor Investor Application Form, name of the BRLM where the Bid was submitted and payment details thereof at the following address:

**MAASHITLA SECURITIES PRIVATE LIMITED**  
**(UNIT : INFLUX HEALTHTECH LIMITED)**  
451, Krishna Apra Business Square Netaji Subhash Place, Pitampura, North West, New Delhi, Delhi - 110034, India  
Tel No.: 011-47581432;  
**E-mail:** investor.ipo@maashitla.com  
**Investor Grievances Email Id** – investor.ipo@maashitla.com  
**Website:** www.maashitla.com  
**SEBI Registration No.:** INR000004370  
**Contact Person:** Mr. Mukul Agrawal